PILOT STUDY--MOLECULAR BASIS OF MULTIPLE MYELOMA

多发性骨髓瘤是一种疾病，其特征是在骨髓瘤细胞中， 终末分化B淋巴细胞的克隆群体在 骨髓 对于绝大多数的花瓶患者来说，这种病是不治之症 确诊后的平均生存期大约是三年。 在过去的几年中，试图改善多发性骨髓瘤的治疗 20年来，只取得了有限的改进。 由于缺乏 成功开发多发性骨髓瘤治愈性疗法， 目前可用的治疗方法，该实验室正在启动研究 旨在更好地了解多发性骨髓瘤生物学。 我们希望对多发性骨髓瘤的发病机制有更好的了解 将允许开发新的治疗性疗法。 迄今为止，对多发性骨髓瘤生物学的研究未能 确定疾病的分子基础。 最近，研究 骨髓瘤细胞中的表面标志物表现出一致的模式， 与浆细胞不同的表面标志物表达。 我们假设 这些差异代表了基因表达模式的改变 由多发性骨髓瘤发病机制中关键的分子事件引起。 为了验证这一假设，我们建议比较骨髓瘤中mRNA的表达， 细胞和正常浆细胞。

Multiple myeloma is a disease characterized by the accumulation of a clonal population of terminally differentiated B lymphocytes within the bone marrow. For the vase majority of patients, the disease is incurable and average survival from diagnosis is approximately three years. Attempts to improve upon therapy for multiple myeloma over the last twenty years have resulted in only modest improvements. Due to the lack of success in developing curative therapy for multiple myeloma using currently available treatments, this laboratory is initiating studies designed to provide a better understanding of multiple myeloma biology. We hope that a better understanding of pathogenesis of multiple myeloma will permit the development of novel curative therapies. Studies into the biology of multiple myeloma have thus far failed to identify the molecular basis of the disease. Recently, studies of surface markers in myeloma cells exhibit a consistent pattern of surfacemarker expression distinct from plasma cells. We hypothesize that these differences represent an altered pattern of gene expression resulting from molecular events crucial in multiple myeloma pathogenesis. To test this hypothesis, we propose to compare mRNA expression in myeloma cells and normal plasma cells using the differential technique.